Detailed look at what medical cannabis products patients actually buy in New York
A cross-sectional study characterized the cannabis products purchased from a single New York State manufacturer, providing rare real-world data on medical cannabis product selection patterns.
Quick Facts
What This Study Found
This study examined medical cannabis product purchases in New York State from dispensaries operated by a single integrated manufacturer, characterizing what products patients actually selected in a tightly regulated market.
Key Numbers
New York State dispensary purchase data from a single integrated manufacturer-retailer. Specific product details characterized.
How They Did This
Cross-sectional study of medical cannabis product purchases made in New York State dispensaries operated by a single licensed manufacturer and retail company. Published in JAMA Network Open.
Why This Research Matters
Most medical cannabis research relies on self-report. This study uses actual purchase data from a regulated market, providing objective insight into patient product preferences.
The Bigger Picture
As medical cannabis markets mature, understanding actual purchasing behavior helps regulators, clinicians, and researchers align product availability with patient needs.
What This Study Doesn't Tell Us
Single manufacturer in one state. New York had one of the most restrictive medical cannabis programs at the time. May not represent patient preferences in less regulated markets.
Questions This Raises
- ?Do patients in less restrictive states choose different products?
- ?Does product type influence treatment outcomes?
Trust & Context
- Key Stat:
- Real purchase data from a regulated NY dispensary system
- Evidence Grade:
- Cross-sectional study using objective purchase data from a regulated market, published in JAMA Network Open.
- Study Age:
- Published in 2022.
- Original Title:
- Characterization of Cannabis Products Purchased for Medical Use in New York State.
- Published In:
- JAMA network open, 5(8), e2227735 (2022)
- Authors:
- Kritikos, Alexandra F(2), Pacula, Rosalie Liccardo(18)
- Database ID:
- RTHC-03981
Evidence Hierarchy
A snapshot of a population at one point in time.
What do these levels mean? →Frequently Asked Questions
What medical cannabis products do patients actually buy?
This study used real purchase data from New York State dispensaries to characterize product selection, providing objective data rather than relying on patient self-report.
Does the type of medical cannabis product matter?
By documenting what patients actually purchase in a tightly regulated market, this study helps establish baseline data for future research on whether product type affects outcomes.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-03981APA
Kritikos, Alexandra F; Pacula, Rosalie Liccardo. (2022). Characterization of Cannabis Products Purchased for Medical Use in New York State.. JAMA network open, 5(8), e2227735. https://doi.org/10.1001/jamanetworkopen.2022.27735
MLA
Kritikos, Alexandra F, et al. "Characterization of Cannabis Products Purchased for Medical Use in New York State.." JAMA network open, 2022. https://doi.org/10.1001/jamanetworkopen.2022.27735
RethinkTHC
RethinkTHC Research Database. "Characterization of Cannabis Products Purchased for Medical ..." RTHC-03981. Retrieved from https://rethinkthc.com/research/kritikos-2022-characterization-of-cannabis-products
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.